USD 2.17
(-0.46%)
Year | Net Debt | Net Debt Growth |
---|---|---|
2023 | 102.66 Million USD | 22.85% |
2022 | 83.56 Million USD | 878.33% |
2021 | -10.73 Million USD | 84.47% |
2020 | -69.14 Million USD | -162.13% |
2019 | -26.37 Million USD | -11.09% |
2018 | -23.74 Million USD | -421.14% |
2017 | -4.55 Million USD | -174.62% |
2016 | 6.1 Million USD | 0.0% |
Year | Net Debt | Net Debt Growth |
---|---|---|
2024 Q2 | 119.74 Million USD | 5.72% |
2024 Q1 | 113.26 Million USD | 10.32% |
2023 Q4 | 102.66 Million USD | 14.07% |
2023 Q1 | 73.55 Million USD | -11.98% |
2023 Q2 | 86.52 Million USD | 17.63% |
2023 FY | 102.66 Million USD | 22.85% |
2023 Q3 | 90 Million USD | 4.02% |
2022 Q3 | 76.57 Million USD | 41.5% |
2022 Q1 | 25.63 Million USD | 338.79% |
2022 Q2 | 54.11 Million USD | 111.08% |
2022 Q4 | 83.56 Million USD | 9.13% |
2022 FY | 83.56 Million USD | 878.33% |
2021 Q3 | -28.9 Million USD | 25.71% |
2021 Q4 | -10.73 Million USD | 62.85% |
2021 Q2 | -38.9 Million USD | 21.04% |
2021 Q1 | -49.26 Million USD | 28.74% |
2021 FY | -10.73 Million USD | 84.47% |
2020 FY | -69.14 Million USD | -162.13% |
2020 Q1 | -14.04 Million USD | 46.75% |
2020 Q2 | -101.92 Million USD | -625.64% |
2020 Q4 | -69.14 Million USD | 25.27% |
2020 Q3 | -92.52 Million USD | 9.23% |
2019 Q2 | -1.24 Million USD | 88.77% |
2019 Q3 | -38.89 Million USD | -3016.51% |
2019 Q4 | -26.37 Million USD | 32.18% |
2019 FY | -26.37 Million USD | -11.09% |
2019 Q1 | -11.11 Million USD | 53.21% |
2018 Q2 | -5.63 Million USD | -121.24% |
2018 FY | -23.74 Million USD | -421.14% |
2018 Q4 | -23.74 Million USD | -220.71% |
2018 Q3 | 19.67 Million USD | 449.38% |
2018 Q1 | 26.5 Million USD | 681.83% |
2017 Q1 | 5.84 Million USD | 0.0% |
2017 Q4 | -4.55 Million USD | 0.0% |
2017 FY | -4.55 Million USD | -174.62% |
2016 FY | 6.1 Million USD | 0.0% |
Name | Net Debt | Net Debt Difference |
---|---|---|
Abbott Laboratories | 8.97 Billion USD | 98.856% |
Allurion Technologies Inc. | 3.82 Million USD | -2587.618% |
Artivion, Inc. | 300.4 Million USD | 65.823% |
Avanos Medical, Inc. | 121.4 Million USD | 15.431% |
Butterfly Network, Inc. | -109.6 Million USD | 193.667% |
Butterfly Network, Inc. | -109.6 Million USD | 193.667% |
Bio-Rad Laboratories, Inc. | 1 Billion USD | 89.753% |
Boston Scientific Corporation | 8.62 Billion USD | 98.81% |
CONMED Corporation | 966.95 Million USD | 89.382% |
Edwards Lifesciences Corporation | -449.1 Million USD | 122.861% |
Paragon 28, Inc. | 36.39 Million USD | -182.122% |
Glaukos Corporation | 290.27 Million USD | 64.631% |
Globus Medical, Inc. | 53.11 Million USD | -93.303% |
Inspire Medical Systems, Inc. | -160.69 Million USD | 163.891% |
Integer Holdings Corporation | 1.01 Billion USD | 89.908% |
Medtronic plc | 24.76 Billion USD | 99.585% |
Myomo, Inc. | -6.27 Million USD | 1737.431% |
Nevro Corp. | 117.61 Million USD | 12.706% |
Owlet, Inc. | -1.34 Million USD | 7756.009% |
Penumbra, Inc. | 66.85 Million USD | -53.562% |
Vicarious Surgical Inc. | -37.99 Million USD | 370.247% |
Smith & Nephew plc | 2.78 Billion USD | 96.31% |
Sonendo, Inc. | 26.34 Million USD | -289.746% |
STERIS plc | 3.17 Billion USD | 96.768% |
Stryker Corporation | 10.02 Billion USD | 98.976% |
Zimmer Biomet Holdings, Inc. | 5.57 Billion USD | 98.16% |